Influence of CYP3A4/5 polymorphisms in the pharmacokinetics of levonorgestrel: A pilot study;Influencia de polimorfismos genéticos de cyp3a4/5 en la farmacocinética de levonorgestrel: Estudio piloto

Biomedica

Volumn 32, Issue 4, 2012, Pages 570-577

  Moreno, Iván ^a   Quiñones, Luis ^a   Catalán, Johanna ^a   Miranda, Carla ^a   Roco, Ángela ^a,b   Sasso, Jaime ^a   Tamayo, Evelyn ^a   Cáceres, Dante ^a   Tchernitchin, Andrei N ^a   Gaete, Leonardo ^a   Saavedra, Iván ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b HOSPITAL SAN JUAN DE DIOS   (Chile)

Author keywords

Hormones; Levonorgestrel; Pharmacogenetics

Indexed keywords

CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; ISOPROTEIN; LEVONORGESTREL;

ADULT; ALLELE; ARTICLE; BIOTRANSFORMATION; BLOOD; CHILE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; METABOLISM; PILOT STUDY; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; YOUNG ADULT;

ADULT; ALLELES; BIOTRANSFORMATION; CHILE; CYTOCHROME P-450 CYP3A; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LEVONORGESTREL; PILOT PROJECTS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROTEIN ISOFORMS; YOUNG ADULT;

EID: 84877114369     PISSN: 01204157     EISSN: None     Source Type: Journal    
DOI: 10.7705/biomedica.v32i4.789     Document Type: Article

References (26)

1. Guengerich FP. Human Cytochrome P450 enzymes. In: Ortiz PR, editor. Cytochrome P450: Structure, mechanism, and biochemistry. Third edition. New York: Kluwer Academic/Plenum Publishers; 2005. p. 377-530.
2. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994;270:414-23.
3. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol. 1998;38:389-430. http://dx.doi.org/10.1146/annurev.pharmtox.38.1.389
4. Guengerich FP. Cytochrome P450 3A4: Regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol. 1999;39:1-17. http://dx.doi.org/10.1146/annurev.pharmtox.39.1.1
5. Frye R, Fitzgerald S, Lagattuta T, Hruska M y Egorin M. Effect of St. John's work on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther. 2004;76:323-9. http://dx.doi.org/10.1016/j.clpt.2004.06.007
6. Brunton LL, Lazo JS, Parker KL. Estrogens and progestins. En: Loose DS, Stancel GM, editors. Goodman & Gilman's The pharmacological basis of therapeutics. 11th edition. New York: McGraw-Hill; 2006. p. 1541-71.
7. Langston A. Emergency contraception: Update and review. Semin Reprod Med. 2010;28:95-102. http://dx.doi.org/10.1055/s-0030-1248133
8. Wagstaff AJ. Continuous-use ethinylestradiol/levonorgestrel20microg/90microg: As an oral contraceptive. Drugs. 2007;67:2473-7.
9. Paine MJ, Scrutton NS, Munro AW, Gutiérrez A, Roberts GC, Wolf CR. Electron transfer partners of cytochrome P450. In: Ortiz PR, editor. Cytochrome P450: Structure, mechanism, and biochemistry. Third edition. New York: Kluwer Academic/Plenum Publishers; 2005. p. 115-48.
10. Yamazaki H, Tsutomu S. Progesterone and testosterone hydroxilation by cytochromes P450 2C19, 2C9 and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997;346:161-9. http://dx.doi.org/10.1006/abbi.1997.0302
11. Stanczyk FZ, Roy C. Metabolism of levonorgestrel, norethindrone and structurally related contraceptive steroids. Contraception. 1990;42:67-96. http://dx.doi.org/10.1016/0010-7824(90)90093-B
12. Suk Wai N, Fan S, Li S, Linan Ch, Ding J, Xiaoping J, et al. A randomized trial to compare 24 h versus 12 h double dose regimen of levonorgestrel for emergency contraception. Hum Reprod. 2005;20:307-11. http://dx.doi.org/10.1093/humrep/deh583
13. Zhao LZ, Zhong GP, Bi H, Ding L, Deng Y, Guan S, et al. Determination of levonorgestrel in human plasma by liquid chromatography-tandem mass spectrometry method: Application to a bioequivalence study of two formulations in healthy volunteers. Biomed Chromatogr. 2008;22:519-26. http://dx.doi.org/10.1002/bmc.963
14. Cavalli SA, Hirata MH, Hirata RD. Detection of MboII polymorphism at the 5' promoter region of CYP3A4. Clin Chem. 2001;47:348-51.
15. Lee SJ, Goldstein JA. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. Pharmacogenomics. 2005;6:357-71. http://dx.doi.org/10.1517/14622416.6.4.357
16. Theron HB, Coetzee C, Sutherland F, Wiesner J, Swart K. Selective and sensitive liquid chromatography-tandem mass spectrometry method for the determination of levonorgestrel in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;813:331-6. http://dx.doi.org/10.1016/j.jchromb.2004.10.039
17. Sambola NC, Harper C, Kim L, Liua Ch, Darney P, Raine T. Pharmacokinetics of single-dose levonorgestrel in adolescents. Contraception. 2006;74:104-9. http://dx.doi.org/10.1016/j.contraception.2006.01.011
18. Nuremberg Doctors' Trial. Declaration of Helsinki (1964). BMJ. 1996;313:1448-9. http://dx.doi.org/10.1136/bmj.313.7070.1448a
19. Food and Drug Administration. Guidance for Industry: E6 Good Clinical Practice: Consolidate guidance. Rockville, MD: U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Control, Center for Biologics Evaluation and Research; 1996.
20. Acuña M, Llop E, Rothhmmer F. Composición genética de la población chilena: las comunidades rurales de los valles del Elqui, Limarí y Choapa. Rev Med Chile. 2000;128:593-600. http://dx.doi.org/10.4067/S0034-98872000000600004
21. Amiramini B, Weber B, Rebbeck T. Regulation of reporter gene expression by a CYP3A4 promoter variant in primary human hepatocytes. Proc Am Assoc Cancer Res. 2000;60:114.
22. Wandel C, Witte J, Hall J, Stein C, Wood A, Wilkinson G. CYP3A4 activity in African American and European American men: population differences in hepatic expression of CYP3A4, relationship to genetic polymorphism in the 5'-upstream regulatory region. Clin Pharmacol Ther. 2000; 68:82-91.
23. Schirmer M, Rosenberger A, Klein K, Kulle B, Toliat M, Nürnberg P, et al. Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. Pharmacogenomics. 2007;8:443-53. http://dx.doi.org/10.2217/14622416.8.5.443
24. Kuehl P, Zhang J, Lin Y, Brockmoller J, Hustert E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383-91. http://dx.doi.org/10.1038/86882
25. Huang W, Lin Y, McConn II D, Calamia J, Totah R, Isoherranen N, et al. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos. 2004;32:1434-45. http://dx.doi.org/10.1124/dmd.104.001313
26. Roco A, Quiñones L, Agúndez JA, García-Martín E, Squicciarini V, Miranda C, et al. requencies of 23 Functionally significant variant alleles related with metabolism of antineoplastic drugs in the Chilean population: comparison with Caucasian and Asian populations. Front Gene. 2010;3:229. http://dx.doi.org/10.3389/fgene.2012.00229